3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
10
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Prostate Cancer Non-Metastatic
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Genital Diseases, Male
1
Biochemically Recurrent Prostate Cancer
1
Adenocarcinoma
1
Interventions
Docetaxel
2
Androgen Antagonists
2
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Metastatic Hormone-sensitive Prostate Cancer
×
darolutamide
×
Clear all
NCT02799602
2025-12-04
ARASENS
Bayer
Phase 3
Completed
1,306 enrolled
25 charts
2 FDA